Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
49.3M
-
Shares change
-
+2.36M
-
Total reported value, excl. options
-
$28.5M
-
Value change
-
+$1.76M
-
Put/Call ratio
-
0.25
-
Number of buys
-
19
-
Number of sells
-
-43
-
Price
-
$0.58
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2022
92 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2022.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.3M shares
of 236M outstanding shares and own 20.88% of the company stock.
Largest 10 shareholders include Alerce Investment Management, L.P. (15.1M shares), VANGUARD GROUP INC (11.2M shares), ACADIAN ASSET MANAGEMENT LLC (7.48M shares), RENAISSANCE TECHNOLOGIES LLC (2.89M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.01M shares), GEODE CAPITAL MANAGEMENT, LLC (1.68M shares), MILLENNIUM MANAGEMENT LLC (1.34M shares), FEDERATED HERMES, INC. (1.02M shares), FMR LLC (614K shares), and STATE STREET CORP (572K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.